Drug eluting graft constructs and methods
The present invention provides, in certain aspects, medical graft products that incorporate multiple drug depots in and/or on the products. One such product is a sheet graft construct, for example for tissue support that includes a sheet graft material with a plurality of drug depots. The drug depots can be hardened deposits formed directly onto the sheet graft material and/or can be capable of eluting a drug for a minimum of 72 hours.
1. An implantable device, comprising:
a sheet graft material having a top side and a bottom side;
a plurality of drug depots attached to the sheet graft material;
wherein the sheet graft material has a porous matrix formed by a network of fibers, the porous matrix having pores formed between the fibers of the network;
wherein the drug depots each comprise solid deposits including a polymeric carrier and at least one drug, the solid deposits each including a first portion infiltrating pores of the porous matrix and a second portion external of the porous matrix;
wherein the sheet graft material has a thickness extending between the top surface and the bottom surface;
wherein the first portions of the drug depots extend only partially through the thickness of the sheet graft material;
wherein each said drug depot covers a corresponding depot-bearing portion of the sheet graft material;
wherein each said depot-bearing portion of the sheet graft material is thinner than depot-free portions of the sheet graft material occurring between the depot-bearing portions;
wherein each said depot-bearing portion of the sheet graft material is denser than the depot-free portions of the sheet graft material occurring between the depot-bearing portions;
wherein the drug depots include 5 or more drug depots each having a top surface with a surface area of about 50 mm 2 to about 500 mm 2 ;
wherein the first portions of the drug depots and the fibers form a hybrid matrix region including fibers entrained within the matrix of the first portions of the drug depots.
2. The implantable device of claim 1 , wherein the sheet graft material comprises an extracellular matrix sheet material.
3. The implantable device of claim 1 , wherein the drug is an antibiotic agent.
4. The implantable device of claim 1 , wherein the drug is gentamycin.
5. The implantable device of claim 1 , wherein the depots are capable of eluting the drug over a period of time greater than about 72 hours when the device is immersed in 66.7 mM phosphate buffered saline at 37° C.
6. The implantable device of claim 1 , wherein the depots are attached to the top side of the sheet graft material, and wherein the depots in combination cover less than about 50% of the surface area of the top side of the sheet material.
7. The implantable device of claim 1 , having from 5 to about 80 of said drug depots attached to the sheet graft.
8. The implantable device of claim 1 , wherein:
each depot-bearing portion has a surface area constituting about 0.5% to about 15% of the surface area of the top surface of the sheet graft material.
9. The implantable device of claim 1 , wherein:
the 5 or more drug depots each having a top surface with a surface area of about 50 mm 2 to about 500 mm 2 are in the form of wafers having a circular, ovoid, or polygonal shape.
10. The implantable device of claim 1 , wherein:
each said depot-bearing portion of the sheet graft material is selectively compressed and thereby less porous and denser than depot-free portions of the sheet graft material occurring between the depot-bearing portions.
11. The implantable device of claim 1 , wherein:
the drug depots are formed by a process including:
depositing a flowable material including a carrier polymer and the at least one drug onto the top side of the sheet graft material so as to form a plurality of deposited material portions; and
hardening the deposited material portions.
12. The implantable device of claim 1 , wherein:
the sheet graft material comprises one or more membranous tissue layers harvested from a source tissue of a warm-blooded vertebrate animal and decellularized, and wherein the network of fibers comprises a network of collagen fibers that retains an inherent network structure from the source tissue.
13. The implantable device of claim 12 , wherein the one or more membranous tissue layers is effective when implanted in a subject to become infiltrated with cells of the subject.
14. The implantable device of claim 12 , wherein the one or more membranous tissue layers is effective when implanted in a subject to become replaced by tissue of the subject.
15. An implantable device, comprising:
a graft material having a porous matrix formed by a network of fibers, the porous matrix having pores formed between the fibers of the network;
a plurality of drug depots including a polymeric carrier and a drug, the drug depots including a first portion infiltrating pores of the porous matrix and a second portion external of the porous matrix, wherein the first portion extends only partially through a thickness of the porous matrix, and wherein the first portion and fibers of the network of fibers form a hybrid matrix region including fibers entrained within material of the first portion;
wherein the drug depots include 5 or more drug depots each having a top surface with a surface area of at least 50 mm 2 ; and
wherein the depots are capable of eluting the drug over a period of time greater than about 72 hours when the device is immersed in 66.7 mM phosphate buffered saline at 37° C.
16. The implantable device of claim 15 , wherein the graft material comprises an extracellular matrix material.
17. The implantable device of claim 15 , wherein the drug is an antibiotic agent.
18. The implantable device of any one of claim 17 , wherein the drug is gentamycin.
19. The implantable device of claim 15 , wherein from 5 to about 80 of said drug depots incorporate at least 80% of a total dose of the drug on the device.
20. An implantable device, comprising:
a sheet graft material having a top side and a bottom side;
a plurality of drug depots attached to the sheet graft material, the drug depots including a polymeric carrier and a drug; and
wherein from 5 to 80 of said drug depots incorporate at least 80% of a total dose of the drug on the device;
wherein 5 or more of the drug depots each have a top surface with a surface area of at least 50 mm 2 ;
wherein, the sheet graft material has a porous matrix formed by a network of fibers, the porous matrix having pores formed between the fibers of the network;
the drug depots comprise solid deposits including a first portion infiltrating pores of the porous matrix and a second portion external of the porous matrix;
wherein the first portions of the drug depots and the fibers form a hybrid matrix region including fibers entrained within the matrix of the first portions of the drug depots.
21. The implantable device of claim 20 , wherein:
the first portions of the drug depots extend only partially through the thickness of the sheet graft material.
22. The implantable device at claim 20 , wherein the drug is gentamycin.